ConvaTec Group (CTEC) Share Price, News & Analysis

Company Overview

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer. In addition, the company offers continence care products and services for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other causes, as well as critical care devices and products used in intensive care units and hospital settings. Further, it provides infusion care solutions comprising disposable infusion sets for diabetes insulin pumps, or for pumps used in continuous subcutaneous infusion treatments for conditions such as parkinson's disease. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. ConvaTec Group PLC was founded in 1978 and is headquartered in London, the United Kingdom.

Key Stats

• Today's Range: 248.64 to 259.80
• 50-Day Range: 236.40 to 269.20
• 52-Week Range: 211.80 to 292
• Volume: 317.52 million shs
• Average Volume: 22.43 million shs
• Market Capitalization: £6.37 billion
• P/E Ratio: 42.17
• Dividend Yield: 2.00%
• Price Target: GBX 301.67
• Consensus Rating: Buy

CTEC Stock Analysis - Frequently Asked Questions

How have CTEC shares performed this year?

ConvaTec Group's stock was trading at GBX 221.20 at the beginning of 2025. Since then, CTEC stock has increased by 13.2% and is now trading at GBX 250.40.
View the best growth stocks for 2025 here.

How were ConvaTec Group's earnings last quarter?

ConvaTec Group PLC (LON:CTEC) announced its quarterly earnings results on Friday, February, 28th. The company reported $12.00 earnings per share for the quarter, missing analysts' consensus estimates of $12.70 by $0.70. ConvaTec Group had a trailing twelve-month return on equity of 9.15% and a net margin of 6.96%.

How do I buy shares of ConvaTec Group?

Shares of CTEC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of ConvaTec Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ConvaTec Group investors own include EnQuest (ENQ), Centamin (CEY), Lloyds Banking Group (LLOY), Oxford Biomedica (OXB), Tullow Oil (TLW), Barclays (BARC) and Vodafone Group Public (VOD).

Company Calendar

• Last Earnings: 2/28/2020
• Today: 4/04/2025
• Record date for 5/29 Dividend: 4/17/2025
• Ex-Dividend for 5/29 Dividend: 4/17/2025
• Dividend Payable: 5/29/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Medical Instruments & Supplies
• Sub-Industry: N/A
• Current Symbol: LON:CTEC
• CIK: N/A
• Web: www.convatecgroup.com
• Phone: 44 11 8952 8100
• Fax: N/A
• Employees: 10,000
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: GBX 301.67
• High Stock Price Target: GBX 310
• Low Stock Price Target: GBX 290
• Potential Upside/Downside: +20.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): GBX 5.94
• Trailing P/E Ratio: 42.17
• Forward P/E Ratio: 18.47
• P/E Growth: 0.93
• Net Income: £188.35 million
• Net Margins: 6.96%
• Pretax Margin: N/A
• Return on Equity: 9.15%
• Return on Assets: 5.01%

Debt

• Debt-to-Equity Ratio: 85.32
• Current Ratio: 2.26
• Quick Ratio: 0.96

Sales & Book Value

• Annual Sales: £2.71 billion
• Price / Sales: 2.35
• Cash Flow: GBX 14.72 per share
• Price / Cash Flow: 17.01
• Book Value: GBX 80.01 per share
• Price / Book: 3.13

Miscellaneous

• Outstanding Shares: 2,543,000,740
• Free Float: N/A
• Market Cap: £6.37 billion
• Optionable: Not Optionable
• Beta: 0.64